dm+d

Unassigned

New Medicines

Bullous pemphigoid

Information

New molecular entity
Akari Therapeutics
Akari Therapeutics

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Inhibitor of two cytokines, complement C5 and lipid mediator leukotriene B4 (LTB4)
BP is a severe autoimmune inflammatory blistering skin disease. It is most common in the elderly and primarily treated with steroids and immunosuppressants. It affects around 100,000 people in the UK and Europe. There is evidence that both complement component C5 and LTB4 have a central role in the disease [1].
Bullous pemphigoid
Subcutaneous injection